XERS · ISSUER CIK 1867096
Xeris Biopharma Holdings, Inc.
Between Aug 1, 2026 and Oct 29, 2026, 4 Xeris Biopharma Holdings, Inc. insiders reported $0.00 of open-market purchases and $1.2M of sales on SEC Form 4.
↗4 insiders filed
Original Form 4 filings from Aug 1, 2026 to Oct 29, 2026. 10 of 10 sales were reported under a 10b5-1 plan.
$0.00Insider buying
$1.2MInsider selling
−$1.2MNet open-market
Oct 2, 2026Latest filing
| Ticker | Insider | Type | Owned | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Oct 2, 202616:54 | Oct 1, 2026 | XERS | See Remarks | S · Sell10b5-1 | $9.41 | −5,000 | 1,351,053 | -0% | −$47K | ||
| Oct 2, 202616:54 | Oct 1, 2026 | XERS | See Remarks | S · Sell10b5-1 | $9.41 | −15,000 | 1,599,208 | -1% | −$141K | ||
| Oct 2, 202616:54 | Oct 1, 2026 | XERS | See Remarks | S · Sell10b5-1 | $9.41 | −16,666 | 1,111,130 | -1% | −$157K | ||
| Sep 29, 202616:59 | Sep 28, 2026 | XERS | See Remarks | S · Sell10b5-1 | $10.00 | −25,000 | 1,614,208 | -2% | −$250K | ||
| Sep 1, 202618:21 | Sep 1, 2026 | XERS | See Remarks | S · Sell10b5-1 | $8.49 | −15,000 | 1,639,208 | -1% | −$127K | ||
| Sep 1, 202618:21 | Sep 1, 2026 | XERS | See Remarks | S · Sell10b5-1 | $8.49 | −16,666 | 1,127,796 | -1% | −$141K | ||
| Sep 1, 202618:20 | Sep 1, 2026 | XERS | See Remarks | S · Sell10b5-1 | $8.50 | −5,000 | 1,356,053 | -0% | −$43K | ||
| Aug 21, 202616:23 | Aug 1, 2026 | XERS | See Remarks, Director | F · TaxLate 20d | $8.08 | −36,645 | 2,898,933 | -1% | $296K | ||
| Aug 21, 202616:15 | Aug 1, 2026 | XERS | See Remarks | F · TaxLate 20d | $8.08 | −21,918 | 1,654,208 | -1% | $177K | ||
| Aug 12, 202616:44 | Aug 12, 2026 | XERS | See Remarks | S · Sell10b5-1 | $8.50 | −5,000 | 1,361,053 | -0% | −$43K | ||
| Aug 4, 202617:30 | Aug 3, 2026 | XERS | See Remarks | S · Sell10b5-1 | $8.02 | −15,000 | 1,676,126 | -1% | −$120K | ||
| Aug 4, 202617:16 | Aug 3, 2026 | XERS | See Remarks | S · Sell10b5-1 | $8.01 | −16,666 | 1,144,462 | -1% | −$134K |